PRO 140 for Human Immunodeficiency Virus Infection

Phase 2

Withdrawn

• Conditions: HIV

• Registration Number: NCT02257788
• Lead Sponsor: Drexel University

Brief Summary

PRO 140 2103 is a multicenter, randomized parallel group study, conducted in male and female adult subjects infected with CCR5-tropic HIV-1.

Detailed Description

Protocol PRO 140 2103 is a multicenter, randomized parallel group study, conducted in approximately 40 male and female adult subjects (n=10/treatment group) infected with CCR5-tropic HIV-1. Subjects will be randomized into one of four treatment groups. Blood samples for drug concentrations, PD variables, and efficacy variables will be obtained over a 59-day period following initiation of dosing. Safety will be monitored throughout the course of the study.

Study Timeline

• Study Start: 2014-09
• Study First Submitted: 2014-10-02
• Study First Submitted QC: 2014-10-02
• Study First Posted: 2014-10-06
• Primary Completion: 2015-02
• Study Completion: 2015-02
• Status Verified: 2017-03
• Last Update Submitted: 2017-03-07
• Last Update Posted: 2017-03-09

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Males and females, age ≥18 years
2. Has not taken any antiretroviral therapy (ART) within 12 weeks of the early screening visit
3. Screening plasma HIV-1 RNA ≥ 5,000 copies/mL
4. CD4+ lymphocyte cell count ≥500 cells/mm3 and no documented count less than or equal to 250 cells/mm3
5. Exclusive CCR5-tropic virus as determined by as determined by the Enhanced Sensitivity Trofile™ HIV Tropism Assay
6. Clinically normal resting 12-lead ECG at screening visit
7. Women of reproductive potential must have a negative serum pregnancy test at Late Screening Visit. Within hours prior to receiving the first dose of study drug, women of reproductive potential must have a negative urine pregnancy test. Male and female subjects must agree not to participate in a conception process and agree to use one barrier method of contraception plus one other highly reliable contraceptive method from the early screening visit through three weeks after the last administered subcutaneous dose of PRO 140.

Exclusion Criteria

1. CXCR4-tropic virus, dual/mixed tropic (R5X4) virus as determined by the Enhanced Sensitivity Trofile™ HIV Tropism Assay
2. Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study
3. Diagnosis of acute viral hepatitis (defined as any active infection with hepatitis A or a new diagnosis of hepatitis B or C within 24 weeks of dosing)
4. Chronic hepatitis
5. Prior use of any entry, attachment, CCR5 coreceptor, or fusion inhibitor, including PRO 140, experimental or approved
6. Any immunization or vaccination (including influenza vaccine) within 30 days prior to administration of study drug.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Maximum change in viral load following initiation of different dosing regimens of PRO140	59 days	Viral Load is Defined as HIV-1 Copies/mL and Expressed as log10 Copies/mL

Trial Locations

Locations (7)

Stanford University (Stanford AIDS Clinical Trials Unit); 🇺🇸 Stanford, California, United States

University of Colorado Denver (Colorado ACTU); 🇺🇸 Denver, Colorado, United States

Washington University in St. Louis; 🇺🇸 St. Louis, Missouri, United States

University of Rochester Medical Center; 🇺🇸 Rochester, New York, United States

Drexel University College of Medicine; 🇺🇸 Philadelphia, Pennsylvania, United States

University of Pennsylvania; 🇺🇸 Philadelphia, Pennsylvania, United States

University of Texas Health Science Center at Houston (Houston AIDS Research team (HART); 🇺🇸 Houston, Texas, United States